Zerion Pharma has elected Carl-Åke Carlsson as its new Chairman of the Board of Directors.

“We are excited to welcome Mr. Carlsson to our leadership team,” said Ole Wiborg, CEO of ZERION, and continues: “ZERION stands in front of significant opportunities on the path to commercialise our Dispersome® technology platform, and I am convinced that Mr. Carlsson will be able to make a great contribution in both setting and implementing the strategic direction to exploit these opportunities to their maximum.”

Carl-Åke Carlsson

Carl-Åke Carlsson brings over three decades of leadership and strategic experience in the pharmaceutical industry and embodies Scandinavian diversity, describes the company., Born in Norway with Swedish ancestry and having spent over a decade living and working in Denmark. Carl-Åke joins Zerion’s Board after 15 years as CEO of Xellia Pharmaceuticals, specializing in anti-infective and critical care treatments. Under his leadership, Xellia transitioned from a Scandinavian entity to a global contender, boasting annual sales to USD 300 million and a robust team of around 1,800 employees.

“I’m excited to join ZERION in this important role. I believe the company’s technology holds immense potential, and I’m eager to contribute to the company’s growth and innovation,” Mr. Carlsson commented.

Before his tenure at Xellia, Mr. Carlsson held several leadership roles at Alpharma. For a decade, he was integral to the top leadership, overseeing business within pharmaceutical retail, specialty institutional markets, and the extensive global B2B sectors, writes Zerion Mr. Carlsson is also serving at prominent board positions, including the biotech company Vectron Biosolutions and Lecka Alpha Trading LP.

Photo: iStock